Literature DB >> 10389036

The social consequences for families with Alzheimer's disease patients: potential impact of new drug treatment.

A Wimo1, B Winblad, M Grafstrom.   

Abstract

The social consequences of Alzheimer's disease are highlighted in this review with regard to impact on family situation, a changing treatment context caused by demographic changes, reorganization of long-term care, a financial crisis in the public health systems and the introduction of antidementia drugs. In the early phase of dementia there may be significant consequences for the patients and the family members which are largely unrecognized by the healthcare system. As the disease progresses, the impact on caregivers in terms of physical and emotional burden, financial and employment status may be enormous. The current care provision in Sweden, the UK and The Netherlands is described. Innovative care alternatives and strategies may improve the situation. The introduction of antidementia drugs such as the acetylcholine esterase inhibitors may also contribute to improved circumstances for patients and caregivers. There is still a great need for further research in this field.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389036     DOI: 10.1002/(sici)1099-1166(199905)14:5<338::aid-gps909>3.0.co;2-1

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  11 in total

Review 1.  Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.

Authors:  H M Lamb; K L Goa
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.

Authors:  Anders Wimo; Bengt Winblad; Albrecht Stöffler; Yvonne Wirth; Hans-Jörg Möbius
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Both targeted mass spectrometry and flow sorting analysis methods detected the decreased serum apolipoprotein E level in Alzheimer's disease patients.

Authors:  Sun-Ho Han; Jun Seok Kim; Youngju Lee; Heesun Choi; Jong-Won Kim; Duk Lyul Na; Eun Gyeong Yang; Myeong-Hee Yu; Daehee Hwang; Cheolju Lee; Inhee Mook-Jung
Journal:  Mol Cell Proteomics       Date:  2013-12-08       Impact factor: 5.911

Review 5.  Assistive technology for memory support in dementia.

Authors:  Henriëtte G Van der Roest; Jennifer Wenborn; Channah Pastink; Rose-Marie Dröes; Martin Orrell
Journal:  Cochrane Database Syst Rev       Date:  2017-06-11

Review 6.  Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.

Authors:  Anders Wimo
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 7.  The Clock Drawing Test versus Mini-mental Status Examination as a Screening Tool for Dementia: A Clinical Comparison.

Authors:  Delnaz Palsetia; G Prasad Rao; Sarvada C Tiwari; Pragya Lodha; Avinash De Sousa
Journal:  Indian J Psychol Med       Date:  2018 Jan-Feb

Review 8.  Economic considerations in the management of Alzheimer's disease.

Authors:  Carolyn W Zhu; Mary Sano
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

9.  Ethical challenges related to elder care. High level decision-makers' experiences.

Authors:  Anna-Greta Mamhidir; Mona Kihlgren; Venke Sorlie
Journal:  BMC Med Ethics       Date:  2007-04-10       Impact factor: 2.652

10.  The Impact of Alzheimer's Disease on the Chinese Economy.

Authors:  Marcus R Keogh-Brown; Henning Tarp Jensen; H Michael Arrighi; Richard D Smith
Journal:  EBioMedicine       Date:  2015-12-22       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.